NASDAQ:JUNS Jupiter Neurosciences Q4 2024 Earnings Report $0.23 -0.01 (-4.58%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$0.23 +0.00 (+0.43%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Jupiter Neurosciences EPS ResultsActual EPS-$0.05Consensus EPS -$0.02Beat/MissMissed by -$0.03One Year Ago EPSN/AJupiter Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJupiter Neurosciences Announcement DetailsQuarterQ4 2024Date3/28/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Jupiter Neurosciences Earnings HeadlinesJupiter Neurosciences (NASDAQ:JUNS) Shares Down 4.6% - Should You Sell?3 hours ago | americanbankingnews.comJupiter Neurosciences Inc.May 30, 2026 | barrons.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free. | Behind the Markets (Ad)D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. in Connection with its ~$2 Million Registered Direct OfferingMay 27, 2026 | finanznachrichten.deJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s DiseaseMay 27, 2026 | markets.businessinsider.comJupiter Neurosciences, Inc. Initiates Patient Enrollment for Phase 2a RESET Trial of JOTROL™ in Parkinson’s DiseaseMay 27, 2026 | quiverquant.comQSee More Jupiter Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email. Email Address About Jupiter NeurosciencesJupiter Neurosciences (NASDAQ:JUNS), a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.View Jupiter Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?Planet Labs: Coming Back Down to EarthDocusign: Another Beat, Another Selloff—Why the Analysts Are WrongA Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowWhat's Make of Macy's: Berkshire Hathaway's Latest BuyA Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
